 Dipeptidyl-Peptidase IV Inhibitors
"Dipeptidyl-Peptidase IV Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release.
| Descriptor ID |
D054873
|
| MeSH Number(s) |
D27.505.519.389.745.335 D27.505.696.422.500
|
| Concept/Terms |
Dipeptidyl-Peptidase IV Inhibitors- Dipeptidyl-Peptidase IV Inhibitors
- Dipeptidyl Peptidase IV Inhibitors
- Inhibitors, Dipeptidyl-Peptidase IV
- Dipeptidyl-Peptidase 4 Inhibitors
- Dipeptidyl Peptidase 4 Inhibitors
- Gliptins
|
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl-Peptidase IV Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl-Peptidase IV Inhibitors".
This graph shows the total number of publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in this website by year, and whether "Dipeptidyl-Peptidase IV Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2008 | 0 | 1 | 1 | | 2011 | 1 | 0 | 1 | | 2013 | 2 | 1 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Dipeptidyl-Peptidase IV Inhibitors" by people in Profiles.
-
Sharma A, Vaduganathan M, Ferreira JP, Liu Y, Bakris GL, Cannon CP, White WB, Zannad F. Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial. J Am Heart Assoc. 2020 01 07; 9(1):e012797.
-
Sharma A, Cannon CP, White WB, Liu Y, Bakris GL, Cushman WC, Zannad F. Early and Chronic Dipeptidyl-Peptidase-IV Inhibition and Cardiovascular Events in Patients With Type 2 Diabetes Mellitus After an Acute Coronary Syndrome: A Landmark Analysis of the EXAMINE Trial. J Am Heart Assoc. 2018 05 16; 7(11).
-
Heller SR, Bergenstal RM, White WB, Kupfer S, Bakris GL, Cushman WC, Mehta CR, Nissen SE, Wilson CA, Zannad F, Liu Y, Gourlie NM, Cannon CP. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial. Diabetes Obes Metab. 2017 05; 19(5):664-671.
-
Cornel JH, Bakris GL, Stevens SR, Alvarsson M, Bax WA, Chuang LM, Engel SS, Lopes RD, McGuire DK, Riefflin A, Rodbard HW, Sinay I, Tankova T, Wainstein J, Peterson ED, Holman RR. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. Diabetes Care. 2016 Dec; 39(12):2304-2310.
-
White WB, Wilson CA, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Heller SK, Mehta CR, Nissen SE, Zannad F, Kupfer S. Angiotensin-Converting Enzyme Inhibitor Use and Major Cardiovascular Outcomes in Type 2 Diabetes Mellitus Treated With the Dipeptidyl Peptidase 4 Inhibitor Alogliptin. Hypertension. 2016 09; 68(3):606-13.
-
Chang E, Kim L, Choi JM, Park SE, Rhee EJ, Lee WY, Oh KW, Park SW, Park DI, Park CY. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Metabolism. 2015 May; 64(5):633-41.
-
Davidson MH. Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
-
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 03; 369(14):1327-35.
-
Cabrera SM, Colvin SC, Tersey SA, Maier B, Nadler JL, Mirmira RG. Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes. Clin Exp Immunol. 2013 Jun; 172(3):375-82.
-
Flynn C, Bakris GL. Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nat Rev Nephrol. 2013 Mar; 9(3):147-53.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|